Email not displaying properly? View email in your browser
SMi's 2nd Annual...
Highly Potent Active Pharmaceutical Ingredients
Finding the balance between safety, quality and cost-effectiveness by addressing containment and cross-contamination issues
Conference: 21st - 22nd May 2018
Workshop: 23rd May 2018
Venue: Holiday Inn, Kensington Forum, London UK

Proud Sponsors:
BSP Pharmaceuticals | Nicomac Europe | Safebridge

Hi Reader,
SMi Group are delighted to announce the 2nd annual Highly Potent Active Pharmaceutical Ingredients (HPAPI) conference, taking place on the 21st - 22nd May 2018, in London UK.
If not, take a look online to see what industry experts you will be networking with this May 2018!

Brief Overview
After a successful launch,SMi are proud to announce the 2nd annual Highly Potent Active Pharmaceutical Ingredients (HPAPI) conference and exhibition taking place this May in London, UK. The global market for Highly Potent Active Pharmaceutical Ingredients has recently experienced an increased growth, resulting from its major use in oncology for cancer treatment - more often in the form of antibody drug conjugates (ADC).
This year's HPAPI conference will feature key speakers of the industry presenting challenges, issues, innovations and new developments in areas of HPAPI production, development and manufacturing, including Bayer, Roche, AstraZeneca, AbbVie, Genentech and many more.
Join us and hear about how working in close proximity with high potency APIs can result in numerous regulations and requirements.
Day 1 Opening Keynote Address -'Practical Approach to HPAPI Manufacturing in Early Development'
Gregory Sowell, Principal Scientific Manager, Small Molecule Process Chemistry, from Genentech will be presenting on day 1 this May, and will be exploring the management of highly potent projects from early development stages. Dr. Sowell has over 25 years of pharmaceutical experience in small molecule process development and manufacturing. He has been at Genentech for the past 10 years where he leads a team of process chemists as well as heads the small molecule GMP API manufacturing facility.
Below is a summary of Gregory's presentation:
  • Designing, building and working in a multiproduct kilo lab environment
  • Risk analysis of entire synthetic process based on factors including process safety and industrial hygiene
  • Important link between surrogate testing of equipment, training staff and process specific equipment needs
  • Ensuring proper transfer of safety information to CMOs

Featured Highlights - May 2018
  • Discover practical approaches to HPAPI manufacturing in a controlled and efficient manner
  • Explore different containment methods and learn about which strategy best suits your needs
  • Evaluate the use of containment risk mitigation tools in early phase development
  • Learn how to manage and effectively and safely dispose of HPAPI, post-production waste
  • Discuss the most important regulations surrounding potent ingredients
Download the complete brochure for more info

Register your place online and take advantage of the early-bird discount ending February 28th, to save 200.

Interested in Sponsoring?
SMi offer sponsorship, exhibition, advertising and branding packages, uniquely tailored to complement your company's marketing strategy. Prime networking opportunities exist to entertain, enhance and expand your client base within the context of an independent discussion specific to your industry.
Benefit from a wide range of tailored packages and network with your future clients by contacting Alia Malick on T: +44 (0)20 7827 6168
For additional details, please do not hesitate to contact us.
Kind Regards,
Follow 'SMi Pharma' on LinkedIn for latest pharmaceutical industry updates.
  Click here to Unsubscribe
Follow Us Facebook Twitter Google + Linkedin - Owned by Ochre Media Pvt. Ltd.
Tel: +91 40 4961 4567  ||  Fax: +91 40 4961 4555